Investor Announcements - 2013

Interim results

16^th Sep 2013

EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2013.

Final results for the year ended 31 December 2012

18^th Mar 2013

Final results for the year ended 31 December 2012.

Establishment of EKF Molecular Diagnostics & Acquisition of 360 Genomics Limited

4^th Mar 2013

EKF Diagnostics announces that it has established a new subsidiary, EKF Molecular Diagnostics Limited (“EKF Molecular”), to focus on molecular and companion diagnostics.

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

What is the difference between standard Viral and Molecular Transport Media?

To support the increase in COVID-19 testing globally, a safe and easy sample collection and transport mechanism is essential. Learn how PrimeStore^® MTM, a novel viral transport media, enables safe molecular testing for multiple pathogens from one sample swab when compared to standard viral transport media.

EKF introduces novel molecular transport media for dual COVID-19 and influenza sampling

Patented PrimeStore^® MTM technology enables safe sample handling and testing for multiple pathogens from one sample swab

EKF opens for live chats at ENDO Online 2020

Patented PrimeStore^® MTM sample collection device deactivates samples for safe sample handling and transport

EKF secures COVID-19 novel sample collection kit manufacturing and supply contracts

Patented PrimeStore^® MTM sample collection device deactivates samples for safe sample handling and transport

EKF & Tosoh Europe N.V. distribution agreement expands HbA1c POC testing reach in Middle East & Africa